Malaria

01Pathophysiology

Malaria begins when an infected female Anopheles mosquito injects sporozoites into the bloodstream during a blood meal. These sporozoites travel rapidly to the liver, where they invade hepatocytes. This is the exoerythrocytic (liver) stage, and it is clinically silent. Inside hepatocytes, sporozoites undergo asexual reproduction to form schizonts, which eventually rupture and release thousands of merozoites into the bloodstream.

A critical concept for the exam is that P. vivax and P. ovale form hypnozoites, which are dormant hepatic stages that can reactivate weeks to years after the initial infection, causing relapsing malaria. This is why primaquine or tafenoquine is required to achieve radical cure for these two species; standard blood-stage treatment alone will not eradicate the infection.

Once merozoites enter the bloodstream, they invade red blood cells (RBCs) and initiate the erythrocytic cycle. Inside the RBC, each merozoite matures through the ring stage (trophozoite), then into a schizont, which ruptures the RBC and releases a new wave of merozoites. This synchronous RBC lysis is directly responsible for the cyclical fever pattern: the release of parasite debris and hemoglobin breakdown products triggers a cytokine storm (TNF-alpha, IL-1, IL-6), producing the classic paroxysm of chills, high fever, and diaphoresis.

Hemolytic anemia results from both direct RBC destruction by parasites and immune-mediated clearance of infected and uninfected RBCs by the spleen, which also explains the hallmark finding of splenomegaly. Elevated indirect bilirubin, elevated LDH, low haptoglobin, and reticulocytosis reflect this ongoing hemolysis.

P. falciparum is the most dangerous species because of a unique mechanism called cytoadherence and sequestration. Infected RBCs express the surface protein PfEMP1 (Plasmodium falciparum erythrocyte membrane protein 1), which binds to endothelial receptors such as ICAM-1 and CD36. This causes infected RBCs to stick to the walls of small blood vessels in the brain, lungs, kidneys, and placenta, leading to microvascular obstruction, tissue hypoxia, and end-organ damage. This is the mechanism behind cerebral malaria (altered consciousness, seizures, coma), acute respiratory distress syndrome (ARDS), acute kidney injury, and placental malaria in pregnant women. Additionally, P. falciparum can infect RBCs of all ages, allowing extremely high parasitemia (>5%), whereas P. vivax preferentially invades reticulocytes and P. malariae targets mature RBCs, limiting their parasite burden.

"Blackwater fever" is a feared complication of severe P. falciparum infection characterized by intravascular hemolysis so intense that free hemoglobin is excreted in the urine, turning it dark brown or black. This can precipitate acute kidney injury.

The protective effect of sickle cell trait (HbAS) is a frequently tested point. Individuals heterozygous for HbS have a survival advantage in endemic areas because P. falciparum-infected RBCs containing HbS undergo sickling and are cleared more rapidly by the spleen, reducing parasite burden. Importantly, sickle cell disease (HbSS) is not protective and carries its own severe complications.

02Classification and Clinical Manifestation

Classification by Species

Classification by Severity (WHO Criteria for Severe Malaria)

Any single criterion in the presence of P. falciparum parasitemia qualifies as severe malaria and mandates parenteral treatment.

03Diagnostic Workup

When a febrile patient presents with a travel history to an endemic region, the best initial test is a Giemsa-stained peripheral blood smear, which includes both thick and thin preparations. The thick smear concentrates parasites and is more sensitive for detecting their presence, while the thin smear preserves RBC morphology, enabling species identification and calculation of the percent parasitemia.

A critical point: if the initial smear is negative but clinical suspicion remains high, repeat the smear every 12 to 24 hours for at least 48 hours (three sets total). Parasites may be sequestered in the microvasculature (particularly P. falciparum) and not circulating at the time of the draw.

Rapid diagnostic tests (RDTs) are useful in resource-limited settings or when microscopy expertise is unavailable. They detect circulating antigens such as HRP-2 (histidine-rich protein 2, produced by P. falciparum) and pLDH or aldolase (produced by all species). RDTs are fast (results in 15 to 20 minutes) but have important limitations: they cannot quantify parasitemia, HRP-2 can remain positive for weeks after successful treatment (not useful for monitoring treatment response), and false negatives can occur with HRP-2 gene deletions.

PCR is the most sensitive and confirmatory test overall. It can detect very low-level parasitemia and distinguish mixed-species infections. However, it is not widely available in acute clinical settings and results may take longer, so it is not the "best initial test" on the exam.

Thrombocytopenia is an extremely common laboratory finding in malaria, present in the majority of cases, and serves as a useful differentiator from other tropical febrile illnesses. However, it is not part of the WHO criteria for severe malaria.

In suspected severe malaria, additional labs should include glucose (hypoglycemia is common, especially in children and pregnant women, and can also be caused by quinine therapy), renal function, arterial blood gas or venous lactate (acidosis), and coagulation studies (DIC screen).

04Management and Treatment

Uncomplicated P. falciparum malaria:
The first-line treatment is an ACT regimen. The most commonly used is artemether-lumefantrine (Coartem): 4 tablets per dose (each tablet contains 20 mg artemether and 120 mg lumefantrine) given as 6 doses over 3 days at hours 0, 8, 24, 36, 48, and 60. Each dose should be taken with a fat-containing meal or drink to enhance lumefantrine absorption. Alternative ACTs include artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine.

For patients unable to take ACT (e.g., in regions where it is unavailable), alternatives include atovaquone-proguanil (Malarone) at 4 adult tablets once daily for 3 days, or quinine sulfate (650 mg orally every 8 hours for 3 to 7 days) combined with doxycycline (100 mg twice daily for 7 days) or clindamycin (20 mg/kg/day divided into 3 doses for 7 days, preferred in pregnant women and children under 8).

Uncomplicated P. vivax, P. ovale, P. malariae:
First-line is chloroquine phosphate: 600 mg base (= 1000 mg salt) orally at time 0, followed by 300 mg base at 6, 24, and 48 hours, for a total dose of 1500 mg base over 3 days. In areas with chloroquine-resistant P. vivax (parts of Indonesia and Papua New Guinea), use an ACT instead.

For P. vivax and P. ovale, chloroquine alone is insufficient because it does not kill hypnozoites. A radical cure requires adding primaquine at 0.25 to 0.5 mg/kg/day for 14 days, or tafenoquine as a single 300 mg dose. Before prescribing either drug, G6PD testing is mandatory. In patients with G6PD deficiency, primaquine causes oxidative hemolytic anemia. For those with mild G6PD deficiency, a modified regimen of primaquine at 0.75 mg/kg once weekly for 8 weeks may be tolerated under close monitoring. In severe G6PD deficiency, primaquine and tafenoquine are absolutely contraindicated, and these patients must be counseled about the risk of relapse.

Severe malaria:
This is a medical emergency. The treatment of choice is IV artesunate, dosed at 2.4 mg/kg IV at 0, 12, and 24 hours, then every 24 hours until the patient can tolerate oral medication (typically after at least 24 hours and once parasitemia drops below 1%). After IV artesunate, transition to a full oral ACT course to complete treatment.

Key supportive measures include aggressive correction of hypoglycemia (monitor glucose every 4 to 6 hours), management of seizures in cerebral malaria (benzodiazepines acutely; avoid prophylactic anticonvulsants), blood transfusion for severe anemia (hemoglobin < 7 g/dL), renal replacement therapy if needed, and airway management in comatose patients. Exchange transfusion is no longer routinely recommended.

Malaria in pregnancy requires careful drug selection. ACTs are considered safe in the second and third trimesters. In the first trimester, use quinine plus clindamycin for 7 days. Primaquine, tafenoquine, and doxycycline are contraindicated throughout pregnancy. For pregnant patients with P. vivax/ovale, defer radical cure (primaquine) until after delivery and instead use chloroquine prophylaxis weekly throughout pregnancy to suppress relapses.

Chemoprophylaxis

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common mistake students make on malaria questions is forgetting to add primaquine (or tafenoquine) for P. vivax and P. ovale. A vignette will describe a patient who was appropriately treated with chloroquine and improved, only to present weeks or months later with a recurrence of fever. The question tests whether you understand that chloroquine alone does not kill hypnozoites in the liver and that radical cure requires a second agent. A closely related trap is failing to check G6PD status before prescribing primaquine. If a question describes a patient with P. vivax malaria and G6PD deficiency, the expected answer is to withhold primaquine and use an alternative approach.

Another common pitfall involves severe malaria management. When a vignette describes a patient with high-grade P. falciparum parasitemia, altered mental status, or any WHO severity criterion, the correct next step is always IV artesunate, not oral ACT. Students sometimes choose oral chloroquine or oral ACT for a critically ill patient, which is incorrect. IV artesunate has clearly demonstrated superiority over IV quinine in reducing mortality in severe malaria (based on the SEAQUAMAT and AQUAMAT trials).

Be alert for hypoglycemia as a complication in two contexts: (1) severe malaria itself, particularly in children and pregnant women, and (2) as a side effect of quinine or quinidine therapy. If a treated malaria patient becomes confused or has a seizure, check glucose before assuming cerebral malaria progression.

Species identification is another area where test-writers place traps. Banana-shaped gametocytes are pathognomonic for P. falciparum and should trigger immediate recognition. Similarly, a smear showing enlarged RBCs with Schüffner stippling points to P. vivax or P. ovale. A question describing nephrotic syndrome in a patient with chronic low-grade fever and a history of travel should make you think of P. malariae. And a 24-hour (quotidian) fever cycle in a patient returning from Southeast Asia with exposure to macaques should raise suspicion for P. knowlesi.

Finally, watch for prophylaxis questions. The exam will test your ability to choose the right prophylactic agent based on the travel destination (chloroquine-sensitive vs. resistant zone), patient profile (pregnancy rules out doxycycline and mefloquine in many guidelines), and timing of start and stop dates. A question about a traveler who followed the correct prophylaxis duration but stopped atovaquone-proguanil only 7 days after return (correct) versus a traveler who stopped doxycycline 7 days after return (incorrect, should be 4 weeks) is a classic test of pharmacologic detail.

The core competency being tested in malaria questions is your ability to integrate travel history, smear findings, and species identification into a coherent diagnostic and therapeutic plan, with particular emphasis on sequencing the right drugs, recognizing severity criteria that change the management pathway, and understanding the pharmacologic rationale behind anti-hypnozoite therapy.